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ABSTRACT
Objective: To assess the feasibility of prospectively
collecting biological samples (urine) from palliative
care patients in the last weeks of life.
Setting: A 30-bedded specialist hospice in the North
West of England.
Participants: Participants were adults with a
diagnosis of advanced disease and able to provide
written informed consent.
Method: Potential participants were identified by a
senior clinician over a 12-week period in 2014. They were
then approached by a researcher and invited to
participate according to a developed recruitment protocol.
Outcomes: Feasibility targets included a recruitment
rate of 50%, with successful collection of samples
from 80% who consented.
Results: A total of 58 patients were approached and
33 consented (57% recruitment rate). Twenty-five
patients (43%) were unable to participate or declined;
10 (17%) became unwell, too fatigued, lost capacity,
died or were discharged home; and 15 (26%) refused,
usually these patients had distressing pain, low mood
or profound fatigue. From the 33 recruited, 20
participants provided 128 separate urine samples, 12
participants did not meet the inclusion criteria at the
time of consent and 1 participant was unable to
provide a sample. The criterion for a urinary catheter
was removed for the latter 6 weeks. The collection rate
during the first 6 weeks was 29% and 93% for the
latter 6 weeks. Seven people died while the study was
ongoing, and another 4 participants died in the
following 4 weeks.
Conclusions: It is possible to recruit and collect
multiple biological samples over time from palliative
care patients in the last weeks and days of life even if
they have lost capacity. Research into the biological
changes at the end of life could develop a greater
understanding of the biology of the dying process.
This may lead to improved prognostication and care of
patients towards the end of life.
INTRODUCTION
Clinicians ﬁnd it difﬁcult to diagnose accur-
ately when someone is dying. There is no
evidence-based method of consistently and
accurately estimating an advanced cancer
patient’s prognosis. Existing methods of pre-
dicting prognosis are no more accurate than
a multiprofessional prognostic estimate.1
Uncertainty has been recognised by health-
care professionals as a great barrier to the
provision of good palliative care.2 This prog-
nostic uncertainty may lead to a lack of
appropriate intervention or prompt inappro-
priate and burdensome interventions.
Accurate prognostication is crucial for
patients, their families, the treating medical
teams and healthcare providers to plan and
provide the best possible care for patients at
the end of life.
Understanding of the biological process of
dying is limited. The current evidence base
informing terminal care is largely descriptive,
retrospective or extrapolated, and there are
no empirical studies investigating biochem-
ical changes during the dying process.3 A
review of end-of-life care in the UK and the
National Care of the Dying audit in hospitals
conducted in England both recommended
Strengths and limitations of this study
▪ This is the first investigation to prospectively
collect biological samples from patients towards
the end of life and in the dying phase.
▪ The study raises the possibility of conducting
systemic research into the biological changes in
patients towards the end of life.
▪ All of the participants who subsequently died on
the study had a cancer diagnosis. It therefore
does not accurately reflect the dying process
patients with a non-cancer diagnosis go through.
▪ The study was found to be acceptable to
patients, their families and the staff; however,
there was no formal process used to assess this.
▪ The protocol described can be used in future
research.
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research into the recognition of dying.4 5 The collection
of biological samples would allow for the use of systemic
research methods including molecular and metabolomic
approaches to investigate the dying process.
Conducting research to understand the biological pro-
cesses at the end of life is difﬁcult due to the numerous
logistical, practical and ethical challenges of collecting
data at this time. Obstacles to research include the fol-
lowing: the heterogeneous nature of the patient popula-
tion due to variants in primary disease and concomitant
and independent comorbidities, the high prevalence of
cognitive problems which affect capacity, the unstable
nature of the disease process, the lack of research infra-
structure and experience in palliative care teams and
‘gatekeeping’ (ie, preventing access to potential research
participants by clinical staff).6 However, research is
essential to improve patient care and for palliative care
to develop as an evidence-based specialty.7
In this paper, we evaluated the feasibility of collecting
multiple biological samples (urine) from hospice
patients in the last weeks and days of life, including
patients who lost the capacity to give consent.
METHODS
Setting and participants
The study was conducted at a 30-bedded specialist
hospice in the North West of England over a 12-week
period during 2014. The hospice provides care for
patients with life-limiting diseases with cancer and non-
cancer diagnoses. Ethics approval was provided by North
Wales (West) Research Ethics Committee (REC refer-
ence 13/WA/0266). Participants were enrolled in the
study, provided that they met eligibility criteria (table 1),
and informed consent was provided.
Enrolment procedure
The research method, including participant selection,
was designed to minimise the potential for distress
caused by recruiting in this challenging and emotive
phase of life. There was extensive discussion among the
team and consultation with a patient advisory group
about the title on the documents used—‘Investigation of
the biological changes in urine towards the end of life—
a feasibility study’. All existing and new inpatients at the
hospice were considered potential participants. A senior
doctor (registrar or consultant) on the clinical team
reviewed each inpatient to evaluate whether an
approach about participation in the study would cause
distress. If deemed appropriate, the patient was provided
with a one-page introductory patient information leaﬂet
and permission for a research team member to
approach was requested. Prior to the study starting, edu-
cation sessions were held with the hospice staff to
outline the purpose of the study and what would be
involved. A research team member then approached the
potential participant and discussed a detailed three-page
patient information leaﬂet, which explained the purpose
of the study as follows: “we plan to analyse the urine of
patients with advanced disease and how this changes
towards the end of life. There is very little known about
changes in a person’s body at this incredibly important
time. By doing this study we want to examine if the phys-
ical experiences of the patient can be seen in the genes
and in the chemicals found in urine.” The patient was
encouraged to involve their family in their decision-
making and was given appropriate time (minimum
24 hours) to consider their participation and have the
opportunity for further discussion with their family,
friends, hospice clinical staff or research team. The
patient’s agreement to enter the study was documented,
and the signed consent form was placed in the medical
notes; a copy was also given to the patient, and an add-
itional copy was kept for the research site ﬁle. Medical
records and medication charts were reviewed to collect
the age, race, diagnosis and, if appropriate, known
metastases, comorbidities, medications, smoking status
and catheter system used. Some participants were asked
to clarify demographic questions. Once informed
consent was obtained and all inclusion criteria were met,
sample collection began. Participating patients who
were discharged from the hospice and subsequently
readmitted were asked to reconﬁrm their consent to par-
ticipate verbally. The process for enrolment is outlined
in ﬁgure 1.
Sample collection
Since potential participants could lose the ability to
provide consent as the study progressed, participants
were asked speciﬁcally whether they agreed to continue
with sample collection should they lose the ability to
consent. Prior to sample collection, the capacity of the
participant was assessed for ongoing assent to collect
Table 1 Study inclusion criteria
Inclusion criteria Exclusion criteria
▸ Inpatient at the hospice
▸ ≥18 years of age
▸ Patient able to
understand and
communicate in English
▸ Urinary catheter in situ
(weeks 1–6 of study
only)*
▸ Patient unable to provide
fully informed consent
▸ Judgement made by
senior doctor on the
clinical team that
approaching patient about
the study would cause
undue distress
▸ Patients too unwell (this
was a clinical decision
made by the treating
team)
▸ Patient unable to
understand English
*During the first 6 weeks of the study, a urinary catheter was part
of the inclusion criteria. With an amendment to the research ethics
approval, this requirement was withdrawn for the latter 6 weeks of
the study to facilitate increased participation.
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samples. If a participating patient’s clinical condition
deteriorated to the extent that the patient lost capacity
to consent to sample collection, then a consultee was
identiﬁed to advise the researcher about the partici-
pant’s ongoing continuation in the study. The consultee
was selected as per ‘Guidance on nominating a con-
sultee for research involving adults who lack capacity to
consent’ (Department of Health, UK). Initially, a per-
sonal consultee was consulted for advice. They were
ideally someone who knew the participant well but were
not acting in a professional or paid capacity, for
example, next of kin, immediate family, relatives or
friends. If a personal consultee was not identiﬁed or
unable to attend the hospice, then the researcher nomi-
nated a healthcare professional (a hospice doctor or
nurse who was involved in the patient’s care), uncon-
nected with the research who was willing to act as a
nominated consultee. The nominated consultee then
contacted a family member and listened to their views if
it was the ﬁrst time that the participant was unable to
give consent. The ‘consultee’ was given a ‘consultee
information leaﬂet’ and given time to consider it. If
after reading this they were in agreement with the par-
ticipant continuing in the study, they were asked to sign
a ‘consultee declaration form’. Only then was a sample
collected. If the participant continued to lack capacity,
then permission to collect urine was sought from the
personal (or nominated) consultee each time a sample
was collected.
Withdrawal of participants
Patients were informed verbally and with the patient
information leaﬂet that they could withdraw from the
study at any time and no reason for withdrawal was
required. It was emphasised that their clinical care
would not be affected. If a participant withdrew from
the study or the consultee requested withdrawal, no
reason was required. However, when they shared their
reason with the research team or a member of the
healthcare staff, this was recorded in the study database.
Sample collection
Biological samples were collected three times a week by
the research team. Research team members collected
20 mL of urine from participants in a universal con-
tainer. For those participants with a urinary catheter, the
urine was collected using a needle and syringe from the
catheter port. The samples were stored on site in a
locked freezer at −20°C. An anonymised record of the
medication administered was collected.
Feasibility criteria
We designed a priori criteria which included the follow-
ing conditions: recruitment rate of at least 50% and the
collection of urine samples from 80% of those who con-
sented. There are no established precedents for what
constitutes successful recruitment within a feasibility
study of this type. However, we have engaged the out-
comes from the Prognosis in Palliative care Study
(PiPS), which is the closest in terms of focus to set the
bar for recruitment. The PiPS study recruited 43%
within a hospice setting, and we decided to target 50%.1
Hagen et al state that palliative care studies can have
attrition rates of 50% or higher.8 Despite this, we aimed
for a collection rate of 80%.
Statistical analysis
The primary reason for this study was to establish feasi-
bility of collecting biological samples from patients in
the last weeks of life. The target sample size was n=20,
which was determined primarily based on feasibility con-
siderations to test procedures for a larger study. The
sociodemographic and outcome variables are reported
using descriptive measures including the mean for con-
tinuous variables and number (per cent) for categorical
variables. The analysis of feasibility outcomes was
descriptive in nature, with the results expressed as per-
centages and feasibility assessed against the correspond-
ing targets.
RESULTS
In total, 128 separate samples from 20 different partici-
pants were collected (see table 2). Four participants lost
capacity while on the study, and the consultee declar-
ation form worked well in facilitating the continued
sample collection for these participants.
Fifty-six per cent (n=58) of inpatients at the hospice
were approached. Of the patients who were not
approached, 53% did not have capacity (eg, dementia,
brain primary or secondary, delirium), 16% were actively
dying, 13% had too short an admission and 17% were
deemed inappropriate to approach (anxiety 13%, anger
2%, low mood 2%).
From the 58 patients approached, 33 consented to
participate in the study (57%). No problems were
Figure 1 Process for enrolment.
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identiﬁed with the information leaﬂets and consent
form used. Only one patient asked a researcher to leave
during the discussion of the patient information leaﬂet.
The protocol used was found to be acceptable to parti-
cipants, their families and staff, and no episodes of dis-
tress were encountered. This was not formally assessed;
however, no symptoms were received regarding the dis-
cussion of the study protocol in recruitment, or the col-
lection of study data and only one patient asked a
researcher to leave during the discussion of the patient
information leaﬂet. One participant withdrew from the
study (5%). One patient who consented and discharged
was readmitted and reconsented during the study.
Of the 43% who did not consent, 40% of those
approached became unwell, too fatigued, lost capacity,
died or were discharged home. The remaining 60%
refused; usually, these patients had distressing pain, low
mood or profound fatigue. This is summarised in ﬁgure 2.
Within the ﬁrst 6 weeks of the study, 17 patients con-
sented to participate. As a urinary catheter was part of
the study inclusion criteria, only ﬁve of these partici-
pants were eligible to have samples collected (collection
rate of 29%). Owing to the high consent rate and low
collection rate early in the study, an amendment to the
Research Ethics Committee was made to remove having
the urinary catheter as part of the inclusion criteria.
During the latter 6 weeks, following the approved
amendment to the protocol, 15 participants were
recruited (collection rate of 93%). Samples were not col-
lected from one patient despite multiple attempts over a
2-week period. One patient asked to withdraw from the
study after the collection of one urine sample as it was
felt ongoing collection was considered too burdensome.
Seven people died, while the study was ongoing and
another four participants died in the following 4 weeks.
DISCUSSION
Research into the physiology of the dying process is difﬁ-
cult. This paper describes a protocol for the collection
of biological samples (urine) from hospice patients
towards the end of life and during the dying process.
There was a 57% recruitment rate of inpatients and a
collection rate of 93% when urine was collected from
participants with or without a urinary catheter. A total of
128 separate samples from 20 different participants were
collected over the 12-week period.
The study conﬁrms the ability to prospectively recruit
patients and collect multiple urine samples towards the
end of life and in the dying phase, including when a
person has lost the capacity to give consent. The proto-
col used was found to be acceptable, although this was
not formally assessed. One participant withdrew from
the study (5%). Attrition rates of 50% and even higher
have been described in other palliative care studies.8
The methodology used beneﬁted greatly from the input
of the patient representative group and by asking the
medical team to screen patients before a researcher
approached. Four participants lost capacity while on the
study, and the consultee declaration form worked well in
order to continue sample collection. The involvement of
family through the consent process and sample collec-
tion helped in ongoing sample collection in those parti-
cipants when mental capacity was lost. In fact, some
patients and families derived meaning from being able
to contribute to the study.
During the study, the requirement for a urinary cath-
eter as a criterion for sample collection was removed
after 6 weeks. This was due to the low recruitment rate
(29%) when samples were collected from 5 out of 17
patients who had consented to the study. The change
facilitated an increased recruitment rate (93%).
Challenges within the study
Challenges to sample collection included the necessity
for sensitive communication skills, the timing of sample
collection, patients who were unable to sign the consent
form and patient fatigue. During the consenting
Table 2 Summary of participant details and samples
collected
Age (years)
Range 50–90
Mean 70.6
Median 67.5
Sex
Male 9
Female 11
Diagnosis (number of cases)
Cancer
Lung 6
Breast 3
Colorectal 3
Prostate 3
Ovarian 1
Gastric 1
Renal 1
Non-malignant
Multisystem atrophy 1
Motor neuron disease 1
Number of samples collected
Range 1–18
Mean 6
Median 5
Number of samples collected in the weeks before dying
Week 1 15 samples from 6
participants
Week 2 17 samples from 9
participants
Week 3 21 samples from 8
participants
Week 4 10 samples from 6
participants
Participants in the last 4 weeks of
life
11
Participants alive more than
3 months after the study
6
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process, ﬁnding the appropriate words to describe the
rationale for the study required experience and training
in advanced communication skills; both researchers
were experienced palliative medicine physicians. Urine
collection from participants who did not have a urinary
catheter highlighted issues to be considered in future
studies. Participants had variable mobility, and providing
a urine sample could be inconvenient for them if they
were not otherwise going to the toilet. One patient who
consented to the study was unable to provide a sample
despite 6 attempts over a 2-week period. Another patient
was able to provide only one sample over the same time
period. There were some participants who could initially
provide samples, but over time as their disease pro-
gressed and their mobility decreased, samples became
more difﬁcult to collect, which caused gaps in sample
collection. There were also times when it was challen-
ging to engage with the medical teams, for example on
ward round days. This sometimes caused a delay in the
clinical team approaching a patient for initial consent.
Other challenges included two participants who were
unable to write their signature on the consent form, and
those patients with severe fatigue who often felt unable
either for the entire initial discussion or the subsequent
follow-up meeting to consent to the study. Therefore, it
would be important in any future work to keep the
patient information leaﬂets and consent forms as short
as possible.
The majority of participants recruited had a cancer
diagnosis (90%), and all of the samples collected in par-
ticipants who subsequently died had a cancer diagnosis.
As a result, this cohort does not represent the dying
process of people with a non-malignant diagnosis. Also,
all of the participants recruited were of a white British
background and were therefore not a broad cultural
cross section of patients.
Palliative patients can have a variable prognoses
ranging from years to days or hours. Those patients
towards the end of life (in the last weeks of life) are an
important and understudied patient population. It is
imperative that no distress is caused to them or their
families, and this is a concern to all parties involved in
research. However, our protocol addresses these import-
ant concerns. In the hospice, we discussed with the treat-
ing team the appropriateness of patients being included
in the study, for example whether the patient was aware
of the advanced nature of their disease. This could be
considered a form of gatekeeping.
Challenges for future research
This study highlights a cohort of patients who on admis-
sion to a hospice had already lost capacity and therefore
could not take part in the study. In particular, this
included patients with dementia, brain tumours and
those actively dying. In the UK, the Mental Capacity Act
of 2005 prevents the recruitment of patients to research
studies who are unable to give consent. A future chal-
lenge in the UK will be to design studies to include this
cohort of patients.
Prior studies do suggest that palliative patients want to
participate in research,9 10 and our study conﬁrms this.
The consent rate of 57% of those approached was
encouraging and afﬁrmed the importance of conduct-
ing research into end-of-life care for these patients and
their families. The PiPS which recruited palliative
patients from 18 palliative services in the UK had a 43%
recruitment in the hospice setting, demonstrating that
access to palliative patients was signiﬁcantly easier in the
hospice as compared to other settings.6 The PiPS study
and the Rees and Hardy study, which developed a
process of advance consent to enable research to be
undertaken in patients in the terminal phase, reported
that very few patients were distressed when approached.
Rees and Hardy also reported that the consent process
can be very time consuming and emotionally draining
for staff.11
Figure 2 A summary of the
patients approached and
consented during the study.
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Stone et al6 reported that obstacles to research include
the nature of the patient population, the high preva-
lence of cognitive problems, the unstable nature of the
disease process, the lack of research infrastructure and
experience in palliative care teams and ‘gatekeeping’
(ie, preventing access to potential research participants
by clinical staff). Stone et al also mention common
reasons for inaccessibility of patients: died before review,
gatekeeping, discharged before review, patients did not
wish to see a researcher, non-competent patient and
relatives unavailable, researcher unavailable and patient
unavailable. Our own study reﬂected similar challenges,
although we did not ﬁnd gatekeeping to be an issue.
As reported by Rees and Hardy, patients on palliative
care wards often have a poor performance status and
are too unwell to read lengthy patient information
sheets.11 They are therefore unable to give consent. In
addition, patients are often reported to be too anxious
to understand complex study descriptions.12 Therefore,
from our experience and the experience of other
studies, it is important in any future work to keep the
patient information leaﬂets and consent forms as simple
and as short as possible.6 13
Diagnosing when a patient with advanced cancer is
in the last weeks or days of life is a challenge; currently,
no diagnostic test is available.5 Accurate prognostic
information is essential to coordinate and manage care
in response to need, while avoiding burdensome and
unnecessary interventions. Even though little is known
about the biology of dying, it has been suggested that
there may be a common process to dying.14 15 Future
work will involve systemic research approaches includ-
ing metabolomic and genomic analyses of the urine
samples. The aim of this research would be to develop
a greater understanding of the biological process of
dying and identify potential biomarkers for the dying
process.
CONCLUSION
This paper describes a study for the collection of bio-
logical samples from patients towards the end of life
including those without capacity. Importantly, the proto-
col used minimises undue distress to patients or their
families. By incorporating the consultee process, the
protocol overcomes the legal and ethical requirements
in patients who lose mental capacity. It is our hope that
this protocol will aid others to collect samples from what
is considered to be a difﬁcult cohort of patients to study.
Research into the biological changes at the end of life
could develop a greater understanding of the dying
process. This may lead to improved prognostication and
care of patients towards the end of life.
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